Home › Funds › Livforsakringsbolaget Skandia, Omsesidigt › JNJ

Livforsakringsbolaget Skandia, Omsesidigt position in JNJ

JOHNSON & JOHNSON · Health Care

Livforsakringsbolaget Skandia, Omsesidigt reported holding 216,006 shares of JNJ (JOHNSON & JOHNSON) in its Q3 2026 13F filing — a position valued at US$57.2M, representing 1.89% of its reported portfolio and ranking #11 among its reported holdings. Livforsakringsbolaget Skandia, Omsesidigt has disclosed JNJ holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)216.01K sh
Reported value held$57.19M
Portfolio Weight1.89%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Livforsakringsbolaget Skandia, Omsesidigt's JNJ position evolved

Livforsakringsbolaget Skandia, Omsesidigt first disclosed a stake in JNJ in Q3 2023 at 96,537 shares (US$15.0M). The position peaked in Q3 2026 at 216,006 shares, worth US$57.2M. Across 13 filings, Livforsakringsbolaget Skandia, Omsesidigt increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 216,006 shares valued at US$57.2M — a reduction of -6,200 shares quarter over quarter.. Notable position changes include a 44% increase in Q3 2025 (shares rose 11% over the following quarter), a 91% trim in Q4 2025 (shares rose 18% over the following quarter), a 1168% increase in Q1 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 96.54K $15.04M New
Q4 2023 98.88K $15.50M Add
Q1 2024 98.88K $15.64M Hold
Q2 2024 97.88K $14.30M Reduce
Q3 2024 135.77K $21.99M Add
Q4 2024 135.37K $19.58M Hold
Q1 2025 135.37K $22.45M Hold
Q2 2025 135.37K $20.66M Hold
Q3 2025 195.27K $36.20M Add
Q4 2025 16.71K $3.46M Reduce
Q1 2026 211.81K $51.76M Add
Q2 2026 222.21K $56.43M Add
Q3 2026 216.01K $57.19M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JNJ and 13F data

JNJ (JOHNSON & JOHNSON) is a Health Care company. 32 other funds we track also report a position in JNJ — the largest reported positions include BlackRock Inc (US$53.87B), Vanguard Group (US$49.74B), VANGUARD CAPITAL MANAGEMENT LLC (US$41.76B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JNJ

All JNJ fund holders →

FAQ

How long has Livforsakringsbolaget Skandia, Omsesidigt held JNJ?

Livforsakringsbolaget Skandia, Omsesidigt has disclosed JNJ holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Livforsakringsbolaget Skandia, Omsesidigt's current position in JNJ?

As of Q3 2026, Livforsakringsbolaget Skandia, Omsesidigt holds 216.01K shares of JNJ (JOHNSON & JOHNSON), valued at $57.19M, representing 1.89% of its reported portfolio and ranking #11.

Has Livforsakringsbolaget Skandia, Omsesidigt been buying or selling JNJ?

In the latest 13F filing (Q3 2026), Livforsakringsbolaget Skandia, Omsesidigt reduced its position in JNJ. The position peaked in Q3 2026 at 216.01K shares.

Which other funds hold JNJ?

Other major institutional holders of JNJ include BlackRock Inc, Vanguard Group, VANGUARD CAPITAL MANAGEMENT LLC, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.